What's Happening?
Researchers have identified a significant association between accelerated epigenetic aging and reduced left ventricular systolic function in young adults in the U.S. who either acquired HIV perinatally or were perinatally exposed to the virus. This cross-sectional
epigenetic investigation, part of the longitudinal Pediatric HIV/AIDS Cohort Study (PHACS) Cardiac Toxicity Substudy, analyzed 123 young adults, including 75 with perinatally acquired HIV (PHIV) and 48 perinatally HIV-exposed, uninfected peers (PHEU). The study utilized purified monocyte DNA methylation to calculate various epigenetic clock algorithms, such as GrimAge and GrimAge2. Findings indicated that mean GrimAge estimates substantially exceeded chronological ages in both groups, with PHIV participants showing an average excess of 17.9 years and PHEU participants 15.8 years. A higher GrimAge was significantly linked to lower left ventricular ejection fraction z-scores, a measure of heart function. This association remained robust even after adjusting for various demographic and health factors.
Why It's Important?
This research highlights a critical long-term health challenge for young adults with perinatal HIV exposure, suggesting that chronic immune activation and lifelong antiretroviral therapy may accelerate biological aging, particularly affecting cardiovascular health. The observed link between accelerated epigenetic aging and reduced left ventricular systolic function indicates a heightened risk for heart problems in this vulnerable population. Understanding these mechanisms is crucial for developing targeted interventions and monitoring strategies. The study's findings could lead to earlier detection of cardiovascular issues, allowing for timely medical management and potentially improving the quality of life and longevity for individuals living with or exposed to perinatal HIV. It also underscores the need for continued research into epigenetic biomarkers as tools for assessing cardiovascular health.
What's Next?
The study team, led by Michael J. Corley and colleagues, emphasizes that these results support further investigation into monocyte epigenetic aging biomarkers to assess cardiovascular health in young adults with perinatal HIV infection or exposure. Future research will likely focus on longitudinal studies to track the progression of epigenetic aging and its impact on cardiac function over time. This could involve exploring the efficacy of specific interventions, such as modifications to antiretroviral therapy regimens or lifestyle changes, in mitigating accelerated epigenetic aging and preserving cardiovascular health. The identification of these biomarkers could also pave the way for personalized medicine approaches, allowing healthcare providers to tailor preventative and therapeutic strategies based on an individual's epigenetic profile and risk of cardiac dysfunction.
Beyond the Headlines
The concept of 'epigenetic age acceleration' offers a deeper insight into how environmental factors and chronic conditions, like HIV exposure, can influence biological aging beyond chronological age. This study suggests that the biological toll of perinatal HIV exposure is not merely a consequence of the virus itself but also of the body's long-term response and treatment. The use of epigenetic clocks like GrimAge provides a powerful tool to measure this biological age, potentially revealing health risks that might not be apparent through traditional clinical assessments. This research could have broader implications for understanding how various chronic diseases and their treatments impact the aging process at a molecular level, opening new avenues for research into anti-aging interventions and disease prevention strategies across different populations.













